(RTTNews) - Eli Lilly and Co. and Incyte said that a Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib met the primary endpoint of at least 75% improvement of skin inflammation and key secondary endpoint.
The Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib for the treatment of adult patients with moderate- to severe atopic dermatitis. The primary endpoint was defined by the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index at Week 16. The study was conducted in North America.
Atopic dermatitis, or atopic eczema, is a chronic, relapsing skin disease characterized by intense itching, dry skin and inflammation that can be present on any part of the body.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.